Bridging the literature gap: Intravenous propofol for non-operating room anaesthesia in paediatric Wilson’s disease with autism spectrum disorder Authors: Deep Sengupta Published: 2026 Dear Editor, We recently encountered a challenging case involving an 11-year-old male weighing 32 kg, diagnosed with Wilson’s disease, autism spectrum disorder (ASD), and profound hyperactivity, who presented for a magnetic resonance imaging (MRI) scan. A comprehensive review of the existing medical literature reveals a strong and almost exclusive focus on the concerns of general anaesthesia in patients with Wilson’s disease.[1] Existing reports primarily detail the challenges associated with major surgeries, emphasising hepatic impairment, the risk of copper-induced renal toxicity, altered pharmacokinetics of various anaesthetic agents, and unpredictable, often prolonged responses to neuromuscular blocking agents.[2] However, there is a distinct paucity of evidence and clinical guidelines detailing the conduct of non-operating room anaesthesia (NORA)—specifically in the isolated environment of an MRI suite—for paediatric patients with Wilson’s disease, particularly when compounded by severe neuro-behavioural comorbidities. In paediatric patients with severe hyperactivity and ASD, achieving absolute patient immobility during MRI requires deep sedation or general anaesthesia. Our patient was on capsule D-penicillamine 250 mg once daily (OD), syrup sorbiline (tricholine citrate+sorbitol) 10 mL twice daily, and tablet ursodeoxycholic acid 150 mg twice daily. Tablet risperidone was stopped a few weeks ago in view of liver issues. Pre-operative evaluation indicated mild hepatic involvement (elevated transaminases: aspartate transaminase/alanine aminotransferase: 104/160 U/L). There was no history of seizures. Airway evaluation revealed normal findings. Anaesthetic management was performed using a titrated intravenous (IV) propofol regimen without pre-medication, serving as an alternative to the conventional dexmedetomidine-ketamine (dex-ket) combination. Standard clinical monitoring was maintained throughout the 45-minute procedure, including pulse oximetry, electrocardiography, and non-invasive blood pressure measurement. To facilitate painless IV cannulation, a eutectic mixture of local anaesthetics cream was applied to the proposed site under an occlusive dressing 2 hours prior to the procedure. Induction was achieved with an IV propofol bolus of 0.5 mg/kg (16 mg), followed by a maintenance infusion of 25–50 µg/kg/min (48–96 mg/h) delivered via an MRI-compatible infusion pump. Supplemental oxygen was administered at 6 L/min via a face mask, with ventilation continuously monitored via capnography using an end-tidal carbon dioxide (EtCO2) sampling line positioned within the mask. The patient remained haemodynamically stable throughout the sequence with no observed episodes of apnoea. Upon cessation of the infusion, the patient emerged promptly; following a 4-hour uneventful observation period in the recovery unit, the patient was discharged without complications. While the dex-ket regimen is highly popular in paediatric NORA due to its preservation of airway reflexes and spontaneous ventilation, it presents substantial drawbacks in this specific patient subset.[3] Ketamine is known to increase oral secretions and carries a well-documented risk of emergence delirium and post-operative agitation.[4] In a child already exhibiting aggressive hyperactivity and ASD, triggering severe behavioural disturbances during emergence in a remote MRI suite poses a significant safety risk to both the patient and staff. Furthermore, dexmedetomidine relies heavily on hepatic metabolism.[5] In patients with Wilson’s disease and underlying hepatic dysfunction, its clearance can be unpredictable, leading to prolonged recovery times and delayed discharge from the NORA facility. Conversely, IV propofol offers distinct pharmacokinetic and pharmacodynamic advantages for this complex demographic. First, its rapid onset facilitates a smooth, swift induction, which is invaluable when managing an uncooperative, anxious, or aggressive child. Second, while propofol is hepatically metabolised, it also undergoes substantial extrahepatic clearance (primarily pulmonary and renal).[6] This dual pathway makes its clearance profile somewhat more predictable and resilient in the face of mild-to-moderate liver dysfunction compared to agents reliant solely on the liver. Most crucially, propofol provides a rapid, clear-headed emergence. This swift return to neurological baseline is paramount for children with ASD as it minimises post-sedation confusion and the risk of hyperactive outbursts. While the administration of propofol in NORA mandates vigilance due to its dose-dependent respiratory depression and hypotensive effects, careful continuous titration, capnography, and management by an experienced anaesthesia provider easily mitigates these risks. In conclusion, while the perioperative concerns of general anaesthesia in Wilson’s disease are well documented, NORA presents unique logistical and pharmacological challenges that remain underrepresented in the literature. We highlight that for paediatric patients with Wilson’s disease complicated by severe behavioural disorders, IV propofol can provide a smooth recovery and safe emergence. Disclosure of use of artificial intelligence (AI)-assistive or generative tools No artificial intelligence (AI) or generative tools were used in the preparation of this manuscript. Declaration of Patient consent The author certifies that he has obtained all appropriate patient consent forms. In the form, the parents of the patient consented to the images and other clinical information to be reported in the journal. They understand that his name and initials will not be published and due efforts will be made to conceal his identity, but anonymity cannot be guaranteed. Conflicts of interest There are no conflicts of interest.